144 Results
Sort By:
Published on March 20, 2024
A study led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) has demonstrated for the first time that a crucial interface in a protein that drives EGFR resistance to targeted cancer therapies could act as a target for more effective treatments. This research, published in Nature…
Published on June 5, 2023
AstraZeneca notched another win with its tyrosine kinase inhibitor Tagrisso (osimertinib) in early-stage, non-small cell lung cancer. In the ADUARA trial, overall survival (OS) was doubled with Tagrisso compared to placebo. The trial comprised patients with epidermal growth factor receptor-mutated (EGFRm) positive tumors who were treated after surgery. The final…
Published on May 3, 2023
Originally Aired: May 18, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW SHORTLY To be implemented in the clinic, tests must be validated and approved through a regulatory process. Coverage and procedures for mutation types vary among the many available tests. There are various methods for EGFR mutation detection,…
Published on February 15, 2023
CD70 is highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC) representing a promising new target for treatment of cancer cells that remain after a patient receives EGFR tyrosine kinase inhibitor (TKI) therapy. The new research from investigators at The University of Texas MD Anderson Cancer…
Published on September 15, 2021
Grouping epidermal growth factor receptor (EGFR) mutations by structure and function can be used to better match non-small cell lung cancer (NSCLC) patients to the most promising treatments, according to researchers from The University of Texas MD Anderson Cancer Center. The findings, published today in Nature, identify four subgroups of mutations and introduce…
Published on July 14, 2021
Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably. Researchers developed an effective drug that inhibits EGFR and kills cancer cells. However, the tumors can grow back. A team at Cold Spring Harbor Laboratory (CSHL) wanted to…
Published on December 23, 2020
Low levels of a protein called p120 catenin, thought to help prevent tumor formation, may explain why some patients develop resistance to EGFR targeted cancer therapy. In an early-stage study carried out using cancer cell lines, researchers based at the Penn State University College of Medicine showed that cells with…
Published on December 17, 2019
Fluxion Biosciences has launched three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53. The new panels complement the company’s Spotlight 59 pan-cancer panel, and have been validated with Fluxion’s ERASE-Seq variant caller. Spotlight Myeloid is a 478-amplicon panel covering 23 clinically-relevant genes implicated in acute…
Published on June 14, 2017
Trovagene said it will provide its Trovera urine ctDNA biomarker test and services to AstraZeneca, under an agreement whose value was not disclosed. Tovagene’s Trovera EGFR urine liquid biopsy test will initially be used in an open-label prospective biomarker study designed to evaluate whether the combination of noninvasive urine and…
Published on March 25, 2024
Sponsored content brought to you by Liquid biopsy analyses have redefined the constraints of cancer research, offering a noninvasive approach for the detection and monitoring of mutations critical to characterizing disease status. While pioneered primarily in the field of hematological oncology, liquid biopsy is a highly promising approach for monitoring…
Published on March 19, 2024
AstraZeneca is acquiring Fusion Pharmaceuticals for $2B. Fusion is a developer of next-generation radioconjugates (RCs) for precision medicine. Fusion’s lead program is alpha-emitting radiopharmaceutical FPI-2265, a small molecule targeting prostate cancers expressing PSMA (Prostate-specific membrane antigen), which is in Phase II for patients with metastatic castration resistant prostate cancer with…
Published on March 5, 2024
Novo Nordisk today announced it has notched another win for its GLP-1 agonist semaglutide (Ozempic), this time for reducing cardiovascular disease and slowing kidney disease in diabetic patients. The latest results from the FLOW trial suggest the drug cuts risk of death in this population by as much as 24%. …
Published on February 14, 2024
Scientists have discovered the molecular events driving the conversion of EGFR-driven lung adenocarcinoma to an aggressive neuroendocrine cancer indistinguishable from small cell lung cancer (SCLC). For the first time, the team revealed that the Myc oncogene alone is capable of this type of histological transformation in SCLC. The discovery raises…
Published on February 13, 2024
Iambic Therapeutics’ NeuralPLexer consistently outperforms AlphaFold2, according to a new report. The study looked at global protein structure accuracy on both representative structure pairs with large conformational changes and recently determined ligand-binding proteins. Iambic says NeuralPLexer is able to directly predict protein–ligand complex structures solely using protein sequence and ligand…
Published on February 12, 2024
ol.custom-marker { counter-reset: list;}ol.custom-marker > li { list-style: none; counter-increment: list;}ol.custom-marker.parens-after.decimal > li::marker { content: counter(list) “)\a0”;} By Michael N. Liebman Biology embraces the existence of a central dogma, i.e., DNA → RNA → protein, and drug development has embraced its own, i.e., disease → target → drug, but both…